Unverified
Gathered automatically from the outlets below; our newsroom hasn't checked it yet.
Novo-backed Windward Bio targets $1 billion valuation in US IPO
Swiss drug developer Windward Bio Group AG is targeting a valuation of up to $1 billion in its US initial public offering, as a strong run for the biotech IPO market extends into November.